Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
about
Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activityThe Newly Identified T Helper 22 Cells Lodge in LeukemiaPleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) familyExpression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell linesMolecular strategies for detecting chromosomal translocations in soft tissue tumors (review).Breast Implant-Associated Anaplastic Large Cell Lymphoma (ALCL): A Case ReportNucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient.Anaplastic large cell lymphoma: pathological, molecular and clinical features.Translocations involving anaplastic lymphoma kinase (ALK).Nucleolar adaptation in human cancerPrimary cutaneous T-cell lymphomas: a review.A novel role for IL-22R1 as a driver of inflammation.Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancerOver Expression of Nucleophosmin and Nucleolin Contributes to the Suboptimal Activation of a G2/M Checkpoint in Ataxia Telangiectasia Fibroblasts.Fusion FISH imaging: single-molecule detection of gene fusion transcripts in situ.The potential for crizotinib in non-small cell lung cancer: a perspective reviewALK a novel lymphoma-associated tumor antigen for vaccination strategies.Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analysesThe nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas.MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.ALK Inhibitors, a Pharmaceutical Perspective.Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer.What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy.Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma.SEC31A-ALK Fusion Gene in Lung Adenocarcinoma.Nucleophosmin: a versatile molecule associated with hematological malignancies.Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumabAnaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.Efficacy of peripheral blood stem cell transplantation versus conventional chemotherapy on anaplastic large-cell lymphoma:a retrospective study of 64 patients from a single center.Nucleophosmin sets a threshold for p53 response to UV radiation.Anaplastic large cell lymphoma with primary involvement of skeletal muscle: a rare case report and review of the literature.Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Anaplastic lymphoma kinase as a therapeutic target.Molecular diagnostics of non-Hodgkin lymphoma.Detecting and targetting oncogenic fusion proteins in the genomic era.Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.Multi-lineage interrogation of the performance characteristics of a split-signal fluorescence in situ hybridization probe for anaplastic lymphoma kinase gene rearrangements: a study of 101 cases characterized by immunohistomorphology on fixed archiv
P2860
Q24669845-E591D035-5C16-44E5-B609-12AA8993BEB4Q26799454-F69A38F5-D0DB-41FA-BB69-75D4F372E5E9Q28208696-C029D452-B798-4CEF-9D1F-442957CFADB4Q28214508-8AB97E60-DF84-4F2B-B7B6-4EB57D4478B2Q33747747-D13BFBC0-8A2E-41FB-B777-54D6F3159061Q33769443-21C9C7DC-12C3-42BA-A1D0-562F072EF8CCQ33965222-E293ED20-030C-40C6-B733-297BC57D9473Q34374218-AC8EDFE0-C232-406E-9322-B4FEFE0ECAFAQ34405439-F8477708-79D7-4BE1-ADDB-D036E24D2480Q34452742-71F65ED3-1100-4D8D-B2BC-DC42905D0746Q34502896-1DFB00E2-B094-41BF-8468-F7D5CBDBACA9Q34542109-3B2CCCC4-E507-4D8B-9609-FCBF7FEA9149Q34569256-FBB4E578-55BC-4071-8D31-DABCDA415640Q34619273-9F2B4AB3-7576-4C7C-9D9C-5EFE81C2D579Q34793452-315B23B0-4D3C-4359-BAF2-BA85E10B800AQ35133405-58E15152-FC82-4B73-A8D1-8ACCF5A220C0Q35534514-4BB010E8-EDDA-4BF3-99EE-F5B64C26B2D0Q35614635-846F36AE-864E-4AB9-85FC-478C7F08FD64Q35747661-E3E3D3F1-7478-4557-992E-9953EFC99153Q35789063-27B348F6-E9C2-4B45-80AA-055760707435Q35951821-4920BD26-AB3A-4EA7-A5E2-649C10AC7F65Q35972157-0EF188FE-4C1D-4C3E-BDCE-480A5DF0BCBDQ36092910-1E297ACC-50C6-45E2-BC7B-4F8723743A17Q36132014-4E5BA8D1-D7C5-4E3F-98F3-96937DC19C78Q36158713-CA268415-A96C-4F0C-9189-B1C226EF0EC3Q36450307-7DDDEB20-64A8-404F-A62D-B12C589E661BQ36482476-816975E2-1EC7-41DA-AD40-DA839259351AQ36597677-8A08EABF-1893-40D8-A019-F9CF43A7C778Q36714237-926AA111-434F-4080-886E-2A36B97B2A77Q36766720-20A55350-BA73-41B0-8D5A-CED3A3A9F9C9Q36879252-B89FE9B9-2646-4241-82AC-39AE3D95BF59Q37183767-DFA727D6-7BFD-40F6-B18F-2AB4930CD918Q37424634-9DB61DF3-B1B7-41FC-BFAD-8F5908282A0FQ37453264-A874EC1A-4621-4B99-90DB-0DAAC65E4D3EQ38042570-2001C80C-46DE-4C20-BF0A-9F6C5CBACD31Q38045455-B22D7AF7-9902-4B79-8DEE-67A52613DB94Q38089227-0B66C660-D93B-4841-B9AB-46FFACBD0A21Q38336067-B700A306-02D5-4499-A067-059A02323DE1Q38336235-F85076D8-5C59-4F3B-904A-4AED15F273C9Q38442806-18B7DF1C-D4DF-4BEF-AD5A-4B6852394489
P2860
Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pathobiology of NPM-ALK and va ...... lymphoma and other lymphomas.
@ast
Pathobiology of NPM-ALK and va ...... lymphoma and other lymphomas.
@en
Pathobiology of NPM-ALK and va ...... lymphoma and other lymphomas.
@nl
type
label
Pathobiology of NPM-ALK and va ...... lymphoma and other lymphomas.
@ast
Pathobiology of NPM-ALK and va ...... lymphoma and other lymphomas.
@en
Pathobiology of NPM-ALK and va ...... lymphoma and other lymphomas.
@nl
prefLabel
Pathobiology of NPM-ALK and va ...... lymphoma and other lymphomas.
@ast
Pathobiology of NPM-ALK and va ...... lymphoma and other lymphomas.
@en
Pathobiology of NPM-ALK and va ...... lymphoma and other lymphomas.
@nl
P2093
P356
P1433
P1476
Pathobiology of NPM-ALK and va ...... lymphoma and other lymphomas.
@en
P2093
von Wasielewski R
P2888
P304
P356
10.1038/SJ.LEU.2401878
P577
2000-09-01T00:00:00Z
P5875
P6179
1039016993